Answers are grounded in this paper and cite their sources.
Background and PurposeActivation of theα7 nicotinicAChreceptor (nAChreceptor) is considered an attractive target for the treatment of cognitive impairment associated with neurological disorders. Here we describe the novelα7‐nAChreceptor agonistAQW051 as a promising drug candidate for this indication.Experimental ApproachAQW051 was functionally characterizedin vitroand cognitive effects evaluated in rodent behavioural models. Pharmacokinetics and tolerability were evaluated in three phaseIplacebo‐controlled studies in 180 healthy subjects.Key ResultsIn vitro,AQW051 bound with high affinity toα7‐nACh receptorsand stimulated calcium influx in cells recombinantly expressing the humanα7‐nACh receptor.In vivo,AQW051 demonstrated good oral bioavailability and rapid penetration into the rodent brain.AQW051 administered over a broad dose range facilitated learning/memory performance in the object recognition and social recognition test in mice and the water maze model in aged rats. Clinically,AQW051 was well tolerated in healthy young and elderly subjects, with an adverse event (AE) profile comparable with placebo. No seriousAEswere reported and allAEswere either mild or moderate in severity at single oral doses up to 200 mg and multiple daily doses up to 75 mg. Once‐daily oral administration ofAQW051 resulted in continuous exposure and a two‐ to threefold accumulation compared with steady state was achieved by 1 week.Conclusions and ImplicationsThese data support further development ofAQW051 as a cognitive‐enhancing agent, as a therapeutic, for example, inAlzheimer's disease or schizophrenia.
No takes yet. Share an insight, caveat, or question.
Feuerbach et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: